News summary
Pharmaceutical industry annual and quarterly reports show divergence in performancefinaltablepokerclubInvestors are advised to pay attention to performance certainty standardsfinaltablepokercluband turning point industries, such as the improvement in prosperity of the blood products industry and the turning point of the medical device industry. We need to be alert to risks such as policy changes and drug price reductions.
Newsletter text
[The divergence trend of performance in the pharmaceutical industry continues]
Under the influence of factors such as industry policies and the company's operating cycle, the pharmaceutical industry showed performance differentiation in the 2023 annual report and the 2024 first quarterly report.
[Significant differences in performance in the field of innovative drugs]
Innovative drug varieties with different clinical values, competitive landscapes and potential spaces, as well as companies in different business cycles, have all led to the continuation of performance differentiation.
[Generic drugs and imitation innovation transformation companies enter a new stage of development]
Against the background of gradual clearing due to the influence of centralized procurement, the performance of generic drug and generic innovation transformation companies has stabilized after bottoming out, and new growth drivers such as catalytic events of innovative drugs and commercialization have become the focus.
[Speed up at both ends of supply and demand in the blood products industry]
The acceleration of supply and demand in the blood products industry promotes the sustainability and certainty of performance growth and becomes a scarce investment opportunity to improve the industry's prosperity.
[Performance differentiation in CXO and scientific research reagents/services]
Differences in business types and regional distribution of customers have led to divergence in the performance of the CXO and scientific reagent/service industries in 2023 and the first quarter of 2024.
[The medical device industry faces turning point]
The medical equipment industry is expected to usher in an inflection point after the resumption of bidding and procurement and the implementation of equipment renewal policies, while the disposable glove industry has entered a cycle of profitability improvement.
[Risk warnings cannot be ignored]
Investing needs to be alert to risks such as unexpected changes in medical insurance negotiations and centralized drug procurement policies, failure in research and development of innovative drugs or falling short of expectations.
